文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

COVID-19患者中的神经阻滞剂恶性综合征

Neuroleptic malignant syndrome in patients with COVID-19.
PubMed 文献 · Am J Emerg Med · 2020-05-22
一句话结论COVID-19重症患者使用镇静剂或抗精神病药期间出现高热、CK升高、心动过速、意识改变和出汗时应警惕神经阻滞剂恶性综合征(NMS)。

本文报告了首两例接受重症监护(包括法匹拉韦)的COVID-19患者被临床诊断为神经阻滞剂恶性综合征(NMS)。病例1为46岁男性,COVID-19相关ARDS,使用法匹拉韦、芬太尼、丙泊酚、罗库溴铵,第3天开始咪达唑仑深镇静,第5天体温升至41.2°C、CK升高,出现心动过速、呼吸急促、意识改变和出汗,怀疑NMS并开始支持治疗,高热持续4天后于第9天消退。病例2为44岁男性,COVID-19相关ARDS,使用法匹拉韦,第5天因谵妄开始利培酮,第7天体温骤升至40.8°C、CK升高,出现心动过速、呼吸急促、意识改变和出汗,确诊NMS,第8天停用法匹拉韦和利培酮,同日CK下降,第9天体温正常。作者指出COVID-19患者常需深镇静并出现谵妄,应更加关注使用此类致病药物患者中NMS的发生;法匹拉韦治疗COVID-19患者发生NMS的机制尚不清楚,因此管理COVID-19患者时需仔细考虑NMS的发生。

要点

  • COVID-19重症患者使用法匹拉韦、咪达唑仑、利培酮等药物期间出现高热、CK升高、心动过速、呼吸急促、意识改变和出汗时,应怀疑NMS。
  • 病例1:46岁男性COVID-19相关ARDS,第5天体温升至41.2°C,怀疑NMS后开始支持治疗,高热持续4天后于第9天消退。
  • 病例2:44岁男性COVID-19相关ARDS,第5天因谵妄开始利培酮,第7天体温骤升至40.8°C,确诊NMS后第8天停用法匹拉韦和利培酮,第9天体温正常。
  • COVID-19患者常需深镇静并出现谵妄,使用此类致病药物时应更加关注NMS的发生。
  • 法匹拉韦治疗COVID-19患者发生NMS的机制尚不清楚,管理COVID-19患者时需仔细考虑NMS的发生。

适用人群与场景

  • 接受重症监护(包括法匹拉韦)的COVID-19患者。

处置流程与药物剂量

  • 病例1:怀疑NMS后开始支持治疗。
  • 病例2:确诊NMS后于第8天停用法匹拉韦和利培酮。

红旗征与不能漏的情况

  • 使用法匹拉韦、咪达唑仑、利培酮等药物期间出现高热(病例1体温41.2°C,病例2体温40.8°C)、CK升高、心动过速、呼吸急促、意识改变和出汗,需警惕NMS。

研究设计与关键结果

  • 本文报告了首两例接受重症监护(包括法匹拉韦)的COVID-19患者被临床诊断为NMS。
  • 病例1:46岁男性,COVID-19相关ARDS,使用法匹拉韦、芬太尼、丙泊酚、罗库溴铵,第3天开始咪达唑仑深镇静,第5天体温升至41.2°C、CK升高,出现心动过速、呼吸急促、意识改变和出汗,怀疑NMS并开始支持治疗,高热持续4天后于第9天消退。
  • 病例2:44岁男性,COVID-19相关ARDS,使用法匹拉韦,第5天因谵妄开始利培酮,第7天体温骤升至40.8°C、CK升高,出现心动过速、呼吸急促、意识改变和出汗,确诊NMS,第8天停用法匹拉韦和利培酮,同日CK下降,第9天体温正常。

证据类型、等级与局限

  • 病例报告(两例)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,COVID-19患者常需深镇静并出现谵妄,应更加关注使用此类致病药物患者中NMS的发生。
  • 作者认为,法匹拉韦治疗COVID-19患者发生NMS的机制尚不清楚,管理COVID-19患者时需仔细考虑NMS的发生。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

We report the first two cases of Coronavirus Disease 2019 (COVID-19) who were receiving intensive care including favipiravir, and were clinically diagnosed with neuroleptic malignant syndrome (NMS) to focus attention on NMS in COVID-19 management. Case 1: A 46-year-old-man with acute respiratory distress syndrome (ARDS) caused by COVID-19 infection was being administered favipiravir. Fentanyl, propofol, and rocuronium were also given. On day 3, midazolam administration was initiated for deep sedation. On day 5, his high body temperature increased to 41.2 °C, creatine kinase level elevated, and he developed tachycardia, tachypnea, altered consciousness, and diaphoresis. NMS was suspected, and supportive therapy was initiated. High-grade fever persisted for 4 days and subsided on day 9. Case 2: A 44-year-old-man with ARDS caused by COVID-19 infection was being treated with favipiravir. On day 5, risperidone was started for delirium. On day 7, his body temperature suddenly increased to 40.8 °C, his CK level elevated, and he developed tachycardia, tachypnea, altered consciousness, and diaphoresis. NMS diagnosis was confirmed, and both, favipiravir and risperidone were discontinued on day 8. On the same day, his CK levels decreased, and his body temperature normalized on day 9. Patients with COVID-19 infection frequently require deep sedation and develop delirium; therefore, more attention should be paid to the development of NMS in patients who are being administered such causative agents. The mechanism underlying the occurrence of NMS in COVID-19 patients treated with favipiravir remains unknown. Therefore, careful consideration of NMS development is necessary in the management of COVID-19 patients.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Soh M, Hifumi T, Isokawa S, et al. Neuroleptic malignant syndrome in patients with COVID-19. Am J Emerg Med. 2020. PMID: 32473756. doi:10.1016/j.ajem.2020.05.042

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。